LY341495

LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively[5].

Product Specifications

CAS Number

[201943-63-7]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

MGluR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/LY341495.html

Purity

99.96

Solubility

DMSO : 6 mg/mL (ultrasonic)

Smiles

O=C(O)[C@@H]1[C@H](C1)[C@@](N)(CC2C3=C(C=CC=C3)OC4=C2C=CC=C4)C(O)=O

Molecular Formula

C20H19NO5

Molecular Weight

353.37

Precautions

H315, H319, H335

References & Citations

[1]Pitsikas N, et al. The metabotropic glutamate 2/3 receptor antagonist LY341495 differentially affects recognition memory in rats. Behav Brain Res. 2012 May 1;230 (2) :374-9.|[2]Sutton LP, et al. Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268.J Neurochem. 2011 Jun;117 (6) :973-83.|[3]Linden AM, et al. Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495. Neuropharmacology. 2009 Aug;57 (2) :172-82. Epub 2009 May 27.|[4]Li J, et al. N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. Pain. 2016 Aug;157 (8) :1711-23.|[5]A E Kingston, et al. LY341495 Is a Nanomolar Potent and Selective Antagonist of Group II Metabotropic Glutamate Receptors.Neuropharmacology. 1998;37 (1) :1-12.